A Study of AWT020 in Participants With Advanced Solid Tumors
NCT07822919 is a phase 1 interventional trial sponsored by Anwita Biosciences. As of 21 Nov 2026, it is recruiting participants. It studies AWT020 in Advanced Cancers (Solid Tumors). The registry lists an enrollment of 96 participants at 3 sites in 1 country. The registry lists a start date of 15 Oct 2026 and a primary completion date of 31 Jan 2029. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT07822919 |
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Anwita Biosciences |
| Enrollment | 96 |
| Registered sites | 3 |
| Countries | 1 |
| Conditions | Advanced Cancers (Solid Tumors) |
| Drugs | AWT020 |
| Start | 15 Oct 2026 |
| Primary completion | 31 Jan 2029 |
| Study completion | 28 Feb 2029 |
| Last update posted | 17 Nov 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Harshad Amin, MD
Florida Clinical Trials Group
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Florida Clinical Trials Group
Plantation
Harshad Amin, MDRecruiting
- Scri Oncology Partners
Nashville
Benjamin Garmezy, MDRecruiting
- Next Virginia
Fairfax
Alexander Spira, MDRecruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT07822919
Each answer restates registry values shown on this page.
What is NCT07822919?
NCT07822919 is a phase 1 interventional trial sponsored by Anwita Biosciences. It studies AWT020 in Advanced Cancers (Solid Tumors).
Is NCT07822919 recruiting?
As of 21 Nov 2026, it is recruiting participants. 3 of its 3 sites list their own status as recruiting.
Who leads NCT07822919?
The registry names Harshad Amin, MD (principal investigator, Florida Clinical Trials Group) as the overall official.
Where does NCT07822919 run?
The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT07822919 study?
The registered drug and biological interventions are AWT020.
When is NCT07822919 expected to complete?
The registry lists a primary completion date of 31 Jan 2029 and a study completion date of 28 Feb 2029. The sponsor last updated the record on 17 Nov 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.